The ferroptosis inducer erastin irreversibly inhibits system xc- and synergizes with cisplatin to increase cisplatin's cytotoxicity in cancer cells

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Sato, Mami ^a,c   Kusumi, Ryosuke ^a   Hamashima, Shinji ^b,c   Kobayashi, Sho ^b,c   Sasaki, Satoru ^c   Komiyama, Yuhei ^c   Izumikawa, Takuji ^d   Conrad, Marcus ^e   Bannai, Shiro ^a   Sato, Hideyo ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

^d NIIGATA UNIVERSITY   (Japan)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ERASTIN; GLUTATHIONE; PIPERAZINE DERIVATIVE;

CELL DEATH; DRUG EFFECT; HUMAN; METABOLISM; NECROSIS; NEOPLASM; TUMOR CELL LINE;

CELL DEATH; CELL LINE, TUMOR; CISPLATIN; GLUTATHIONE; HUMANS; NECROSIS; NEOPLASMS; PIPERAZINES;

EID: 85040769180     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-19213-4     Document Type: Article

References (45)

1. Bannai, S. & Kitamura, E. Transport interaction of L-cystine and L-glutamate in human diploid fibroblasts in culture. J. Biol. Chem. 255, 2372-2376 (1980).
2. Sato, H., Tamba, M., Ishii, T. & Bannai, S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J. Biol. Chem. 274, 11455-11458 (1999).
3. Sato, H., Tamba, M., Kuriyama-Matsumura, K., Okuno, S. & Bannai, S. Molecular cloning and expression of human xCT, the light chain of amino acid transport system xc. Antioxid. Redox Signal. 2, 665-671 (2000).
4. Mastroberardino, L. et al. Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 395, 288-291 (1998).
5. Kanai, Y. et al. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J. Biol. Chem. 273, 23629-23632 (1998).
6. Torrents, D. et al. Identification and characterization of a membrane protein (y + L amino acid transporter-1) that associates with 4F2hc to encode the amino acid transport activity y + L. A candidate gene for lysinuric protein intolerance. J. Biol. Chem. 273, 32437-32445 (1998).
7. Bannai, S. Exchange of cystine and glutamate across plasma membrane of human fibroblasts. J. Biol. Chem. 261, 2256-2263 (1986).
8. Kobayashi, S. et al. Cystathionine is a novel substrate of cystine/glutamate transporter: implications for immune function. J. Biol. Chem. 290, 8778-8788 (2015).
9. Bannai, S. & Tateishi, N. Role of membrane transport in metabolism and function of glutathione in mammals. J. Membr. Biol. 89, 1-8 (1986).
10. Bannai, S. Transport of cystine and cysteine in mammalian cells. Biochim. Biophys. Acta 779, 289-306 (1984).
11. Banjac, A. et al. The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death. Oncogene 27, 1618-1628 (2008).
12. Mandal, P. K. et al. System x(c)- and thioredoxin reductase 1 cooperatively rescue glutathione deficiency. J. Biol. Chem. 285, 22244-22253 (2010).
13. Conrad, M. & Sato, H. The oxidative stress-inducible cystine/glutamate antiporter, system x(c)(-): cystine supplier and beyond. Amino Acids 42, 231-246 (2012).
14. Massie, A., Boillee, S., Hewett, S., Knackstedt, L. & Lewerenz, J. Main path and byways: non-vesicular glutamate release by system xc(-) as an important modifier of glutamatergic neurotransmission. J. Neurochem. 135, 1062-1079 (2015).
15. Lo, M., Wang, Y. Z. & Gout, P. W. The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J. Cell. Physiol. 215, 593-602 (2008).
16. Lewerenz, J. et al. The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid. Redox Signal. 18, 522-555 (2013).
17. Bridges, R. J., Natale, N. R. & Patel, S. A. System xc(-) cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br. J. Pharmacol. 165, 20-34 (2012).
18. Conrad, M., Angeli, J. P., Vandenabeele, P. & Stockwell, B. R. Regulated necrosis: disease relevance and therapeutic opportunities. Nat. Rev. Drug Discov. 15, 348-366 (2016).
19. Dolma, S., Lessnick, S. L., Hahn, W. C. & Stockwell, B. R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3, 285-296 (2003).
20. Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060-1072, https://doi.org/10.1016/j. cell.2012.03.042 (2012).
21. Dixon, S. J. et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 3, e02523 (2014).
22. Okuno, S. et al. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br. J. Cancer 88, 951-956 (2003).
23. Patel, S. A., Warren, B. A., Rhoderick, J. F. & Bridges, R. J. Differentiation of substrate and non-substrate inhibitors of transport system xc(-): an obligate exchanger of L-glutamate and L-cystine. Neuropharmacology 46, 273-284 (2004).
24. Patel, S. A. et al. Isoxazole analogues bind the system xc - transporter: structure-activity relationship and pharmacophore model. Bioorg. Med. Chem. 18, 202-213 (2010).
25. Gout, P. W., Buckley, A. R., Simms, C. R. & Bruchovsky, N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 15, 1633-1640 (2001).
26. Jimenez-Vidal, M. et al. Thiol modification of cysteine 327 in the eighth transmembrane domain of the light subunit xCT of the heteromeric cystine/glutamate antiporter suggests close proximity to the substrate binding site/permeation pathway. J. Biol. Chem. 279, 11214-11221 (2004).
27. Yagoda, N. et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447, 864-868 (2007).
28. Gout, P. W., Kang, Y. J., Buckley, D. J., Bruchovsky, N. & Buckley, A. R. Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells. Leukemia 11, 1329-1337 (1997).
29. Huang, Y., Dai, Z., Barbacioru, C. & Sadee, W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 65, 7446-7454 (2005).
30. Chung, W. J. et al. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J. Neurosci. 25, 7101-7110 (2005).
31. Lyons, S. A., Chung, W. J., Weaver, A. K., Ogunrinu, T. & Sontheimer, H. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res. 67, 9463-9471 (2007).
32. Savaskan, N. E. et al. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat. Med. 14, 629-632 (2008).
33. Ishimoto, T. et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19, 387-400 (2011).
34. Jiang, L. et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520, 57-62 (2015).
35. Shukla, K. et al. Inhibition of xc(-) transporter-mediated cystine uptake by sulfasalazine analogs. Bioorg. Med. Chem. Lett. 21, 6184-6187 (2011).
36. Robe, P. A. et al. A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. BMC Cancer 6, 29 (2006).
37. Robe, P. A. et al. Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer 9, 372 (2009).
38. Roh, J. L., Kim, E. H., Jang, H. J., Park, J. Y. & Shin, D. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. Cancer Lett. 381, 96-103 (2016).
39. Seiler, A. et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIFmediated cell death. Cell Metab. 8, 237-248 (2008).
40. Lewerenz, J. et al. Phosphoinositide 3-kinases upregulate system xc(-) via eukaryotic initiation factor 2alpha and activating transcription factor 4 - A pathway active in glioblastomas and epilepsy. Antioxid. Redox Signal. 20, 2907-2922 (2014).
41. Sawicki, J. A., Morris, R. J., Monks, B., Sakai, K. & Miyazaki, J. A composite CMV-IE enhancer/beta-actin promoter is ubiquitously expressed in mouse cutaneous epithelium. Exp. Cell Res. 244, 367-369 (1998).
42. Sato, H. et al. Redox imbalance in cystine/glutamate transporter-deficient mice. J. Biol. Chem. 280, 37423-37429 (2005).
43. Iida, T. et al. Co-expression of gamma-glutamylcysteine synthetase sub-units in response to cisplatin and doxorubicin in human cancer cells. Int. J. Cancer 82, 405-411 (1999).
44. Tietze, F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal. Biochem. 27, 502-522 (1969).
45. Mizushima, S. & Nagata, S. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res. 18, 5322 (1990).